PharmaVOICE - The RWE Evolution
With so much attention being focused on real-world evidence (RWE) and real-world data (RWD), it would be easy to assume that this critical area of drug development is revolutionary. But, in fact, RWE has been around for decades and what the industry is currently experiencing is an evolution of processes founded in solid science and good clinical study practices to support regulatory, payer, and physician stakeholder decisions. That’s not to say there haven’t been some revolutionary forces at play to put patients at the heart of the RWE and RWD movement.
Related Insights
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Article
Guide for Real-World Evidence
May 21, 2021
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Leveraging post-marketing regulatory requirements to drive commercial value
Oct 16, 2024
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Related Insights
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Article
Guide for Real-World Evidence
May 21, 2021
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Leveraging post-marketing regulatory requirements to drive commercial value
Oct 16, 2024
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023